4.8 Article

FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N6-Methyladenosine RNA Demethylase

Journal

CANCER CELL
Volume 31, Issue 1, Pages 127-141

Publisher

CELL PRESS
DOI: 10.1016/j.ccell.2016.11.017

Keywords

-

Funding

  1. NIH R01 grants [CA178454, CA182528, CA214965, GM071440]
  2. Leukemia & Lymphoma Society (LLS) Special Fellowship
  3. LLS Translational Research grant
  4. American Cancer Society (ACS)
  5. ACS-IL Research Scholar grant
  6. Gabrielle's Angel Foundation for Cancer Research
  7. China Scholarship Council (CSC)
  8. Foundation of Innovation Team for Basic and Clinical Research of Zhejiang Province [2011R50015]

Ask authors/readers for more resources

N-6-Methyladenosine (m(6)A) represents the most prevalent internal modification in mammalian mRNAs. Despite its functional importance in various fundamental bioprocesses, the studies of m(6)A in cancer have been limited. Here we show that FTO, as an m(6)A demethylase, plays a critical oncogenic role in acute myeloid leukemia (AML). FTO is highly expressed in AMLs with t(11q23)/MLL rearrangements, t(15;17)/PML-RARA, FLT3-ITD, and/or NPM1 mutations. FTO enhances leukemic oncogene-mediated cell transformation and leukemogenesis, and inhibits all-trans-retinoic acid (ATRA)-induced AML cell differentiation, through regulating expression of targets such as ASB2 and RARA by reducing m(6)A levels in these mRNA transcripts. Collectively, our study demonstrates the functional importance of the m(6)A methylation and the corresponding proteins in cancer, and provides profound insights into leukemogenesis and drug response.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available